AU2009203530B2 - Methods and compositions for oral administration of insulin - Google Patents

Methods and compositions for oral administration of insulin Download PDF

Info

Publication number
AU2009203530B2
AU2009203530B2 AU2009203530A AU2009203530A AU2009203530B2 AU 2009203530 B2 AU2009203530 B2 AU 2009203530B2 AU 2009203530 A AU2009203530 A AU 2009203530A AU 2009203530 A AU2009203530 A AU 2009203530A AU 2009203530 B2 AU2009203530 B2 AU 2009203530B2
Authority
AU
Australia
Prior art keywords
another embodiment
insulin
oil
polysaccharide
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009203530A
Other languages
English (en)
Other versions
AU2009203530A1 (en
Inventor
Orna Gribova
Alexander Vol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oshadi Drug Administration Ltd
Original Assignee
Oshadi Drug Administration Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oshadi Drug Administration Ltd filed Critical Oshadi Drug Administration Ltd
Publication of AU2009203530A1 publication Critical patent/AU2009203530A1/en
Application granted granted Critical
Publication of AU2009203530B2 publication Critical patent/AU2009203530B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2009203530A 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin Ceased AU2009203530B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IL188647 2008-01-08
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US8029508P 2008-07-14 2008-07-14
US61/080,295 2008-07-14
US10202008P 2008-10-02 2008-10-02
US61/102,020 2008-10-02
PCT/IL2009/000037 WO2009087634A2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin

Publications (2)

Publication Number Publication Date
AU2009203530A1 AU2009203530A1 (en) 2009-07-16
AU2009203530B2 true AU2009203530B2 (en) 2013-10-24

Family

ID=40326402

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009203530A Ceased AU2009203530B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
AU2009203529A Ceased AU2009203529B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009203529A Ceased AU2009203529B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents

Country Status (15)

Country Link
US (3) US20100278922A1 (enExample)
EP (2) EP2254590B1 (enExample)
JP (1) JP5432183B2 (enExample)
KR (1) KR101588066B1 (enExample)
AU (2) AU2009203530B2 (enExample)
BR (1) BRPI0906866A2 (enExample)
CA (2) CA2711554C (enExample)
DK (2) DK2231123T3 (enExample)
EA (1) EA018461B1 (enExample)
ES (2) ES2397061T3 (enExample)
IL (3) IL188647A0 (enExample)
MX (1) MX2010007462A (enExample)
NZ (1) NZ586374A (enExample)
WO (2) WO2009087634A2 (enExample)
ZA (1) ZA201004480B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521295Y2 (ja) 1991-11-13 1996-12-25 シーケーディ株式会社 流体混合器
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US9060932B2 (en) 2009-07-09 2015-06-23 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
KR101875155B1 (ko) * 2011-05-02 2018-07-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
WO2014031837A1 (en) * 2012-08-22 2014-02-27 The Regents Of The University Of California Compositions and methods for enhancing sialic acid levels in tissue
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
CA2899220A1 (en) * 2013-01-29 2014-08-07 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes
ES2502691B1 (es) * 2013-09-25 2015-07-07 Sani-Red, S.L. Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
KR102418550B1 (ko) * 2015-11-03 2022-07-06 삼성전자주식회사 포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법
WO2017141262A1 (en) * 2016-02-19 2017-08-24 Indian Institute Of Technology, Bombay Orally administrable pharmaceutical preparation containing protein
EP3485899A4 (en) * 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze THERMOSTABLE COMPOSITION HAVING ANTIVIRAL AND ANTIBACTERIAL ACTION, AND USE THEREOF
IT201800007947A1 (it) * 2018-08-07 2020-02-07 Vetagro Int Srl Metodo per preparare una composizione di aminoacidi per consentire la corrispondenza dei singoli fabbisogni di amminoacidi ad un soggetto in base all'età, al genere, all'attività fisica e alla genetica
EA202192793A1 (ru) 2019-04-11 2022-01-12 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
WO2021053246A1 (en) * 2019-09-20 2021-03-25 University College Dublin Oral delivery system
DK3937983T3 (da) 2019-12-17 2025-05-05 9286 3620 Quebec Inc Oral afliveringssystemer baserede på in situ-dannende protein/polysakkaridkoacervater
WO2021155042A1 (en) 2020-01-28 2021-08-05 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US20240315972A1 (en) 2021-07-12 2024-09-26 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers
CN119630685A (zh) 2022-06-13 2025-03-14 B.A.I.实验室有限责任公司 结合白介素-13的环状寡肽及其使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US20030035888A1 (en) * 2000-01-28 2003-02-20 Yuichi Eriyama Method for manufacturing hydrophobic colloidal silica
US20060204559A1 (en) * 2000-03-23 2006-09-14 Bess William S Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US5874105A (en) 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) * 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2767718B1 (fr) * 1997-08-28 1999-10-22 Oreal Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
ATE246039T1 (de) * 1997-09-09 2003-08-15 Select Release L C Beschichtete teilchen, methode zu ihrer herstellung und verwendung
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) * 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
EP1299348B1 (en) * 2000-06-29 2008-04-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE320267T1 (de) * 2000-08-11 2006-04-15 Lohmann Animal Health Gmbh W/o emulsion adjuvanszuzammensetzungen für impstoffen
US20020150621A1 (en) * 2000-10-16 2002-10-17 Kohane Daniel S. Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) * 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
WO2003055469A1 (en) * 2001-12-21 2003-07-10 Celator Technologies Inc. Improved polymer-lipid delivery vehicles
EP1458361A4 (en) * 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US6824790B2 (en) * 2002-01-09 2004-11-30 Enzrel Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
EP1472351B1 (en) 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US7244498B2 (en) 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
ES2465496T3 (es) 2003-01-06 2014-06-05 Emisphere Technologies, Inc. Terapia de insulina oral nocturna
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
WO2005094785A2 (en) 2003-09-17 2005-10-13 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
EA200600877A1 (ru) * 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20050232981A1 (en) 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US7288134B2 (en) 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20060083781A1 (en) 2004-10-14 2006-04-20 Shastri V P Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
NZ565663A (en) 2005-08-09 2011-03-31 Univ Sunderland The use of hydrophobic silica particles in detecting and identifying fingerprints
US8715739B2 (en) 2005-10-24 2014-05-06 Purdue Research Foundation Polymer coated microparticles
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
US20070184076A1 (en) * 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
AU2007238114B2 (en) * 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US9060932B2 (en) * 2009-07-09 2015-06-23 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US20030035888A1 (en) * 2000-01-28 2003-02-20 Yuichi Eriyama Method for manufacturing hydrophobic colloidal silica
US20060204559A1 (en) * 2000-03-23 2006-09-14 Bess William S Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIN et al. Preparation and Characterization of Nanoparticles Shelled with Chitosan for Oral Insulin Delivery. Biomacromolecules, December 2006, Vol 8, No 1, pp 146-152 *

Also Published As

Publication number Publication date
DK2254590T3 (da) 2013-01-28
AU2009203529A1 (en) 2009-07-16
EP2231123A4 (en) 2011-09-07
WO2009087633A2 (en) 2009-07-16
AU2009203530A1 (en) 2009-07-16
IL206835A (en) 2017-09-28
JP2011509287A (ja) 2011-03-24
CA2711556A1 (en) 2009-07-16
CA2711554C (en) 2017-01-03
US20100297245A1 (en) 2010-11-25
IL206835A0 (en) 2010-12-30
EP2254590A2 (en) 2010-12-01
IL188647A0 (en) 2008-11-03
IL206834A0 (en) 2010-12-30
WO2009087633A3 (en) 2010-03-11
EA201070827A1 (ru) 2010-12-30
KR20100119541A (ko) 2010-11-09
ZA201004480B (en) 2011-09-28
JP5432183B2 (ja) 2014-03-05
NZ586374A (en) 2011-10-28
EP2254590A4 (en) 2012-01-25
US20100278922A1 (en) 2010-11-04
EP2231123B1 (en) 2012-10-24
US20150147399A1 (en) 2015-05-28
MX2010007462A (es) 2010-08-23
DK2231123T3 (da) 2013-02-04
IL206834A (en) 2015-09-24
CA2711554A1 (en) 2009-07-16
BRPI0906866A2 (pt) 2019-02-26
EA018461B1 (ru) 2013-08-30
WO2009087634A2 (en) 2009-07-16
KR101588066B1 (ko) 2016-01-22
EP2254590B1 (en) 2012-10-10
ES2398015T3 (es) 2013-03-13
HK1148945A1 (en) 2011-09-23
WO2009087634A3 (en) 2010-01-07
US9949924B2 (en) 2018-04-24
ES2397061T3 (es) 2013-03-04
AU2009203529B2 (en) 2013-09-05
EP2231123A2 (en) 2010-09-29
US8936786B2 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
AU2009203530B2 (en) Methods and compositions for oral administration of insulin
US9504648B2 (en) Matrix carrier compositions, methods and uses
US20150366946A1 (en) Pharmaceutical compositions for oral treatment of diabetes
HK1148945B (en) Methods and compositions for oral administration of protein and peptide therapeutic agents
Khulbe A REVIEW ON ORAL INSULIN
HK1158934A (en) Matrix carrier compositions, methods and uses
HK1158934B (en) Matrix carrier compositions, methods and uses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired